Physician profile
Nancy V Morris
NPI 1770543175
$17,206.04
in general payments reported to CMS, 2019-2025
50 companies · $2,417 in 2025
The $2,417 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,412 · 2020: $1,573 · 2021: $2,739 · 2022: $2,702 · 2023: $2,778 · 2024: $2,585 · 2025: $2,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,680 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,680.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,776.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,612.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,607.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,418.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,417.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $917.62 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $882.45 | 2019-2024 | Jardiance, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $836.75 | 2022-2025 | |
| Amgen INC. | $673.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $657.13 | 2019-2025 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $531.72 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $497.85 | 2019-2023 | Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $458.80 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $368.37 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $338.27 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.